Author

Xu Feng

Guangzhou Women and Children Medical Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Organism:human· 1 Organism:mouse· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

Bin XiaoiD· 1 shared Chengqi Huang· 1 shared Fangze Qian· 1 shared Gao WentaoiD· 1 shared Han LiangiD· 1 shared Hao Yuan· 1 shared Hongyun ZhaoiD· 1 shared Jianzhen Lin· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Bin XiaoORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Dual histone methylation reader ZCWPW2 links histone methylation to initiation of meiotic recombination

Shenli Yuan, Shiyu Wang, Ziyou Bao, Ziqi Wang, Kang Shangguan, Yelian Yan, Yajun Shi, Xu Feng, Chengqi Huang, Mengrui Fang, Hongyun Zhao, Shigang Zhao, Liu H, Z Chen, Tao Huang

This study identifies ZCWPW2 as a dual histone methylation reader that links H3K4me3 and H3K36me3 to meiotic DSB formation by interacting with key recombination proteins.

bioRxiv · May 26, 2026 · PreprintCell Biology

Co-evolution of Oncogenic KRAS Signaling and LILRBhigh Macrophages Drives Pancreatic Cancer Recurrence

Jianzhen Lin, Zhenzhen Xun, Fangze Qian, Zhigao Chen, Weikang Hu, W. Liu, Yang Wu, Hao Yuan, Lingdi Yin, Yuxing Wang, Xiao Huang, Yujia Dang, Bin Xiao, Junli Wu, Gao Wentao, , Han Liang

This study identifies a co-evolved tumor-immune interaction involving KRAS signaling and LILRBhigh macrophages that drives PDAC recurrence and presents a therapeutic strategy targeting this axis.

bioRxiv · Mar 7, 2026 · PreprintCancer Biology